TEVA-CAPTOPRIL TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

CAPTOPRIL

Saadav alates:

TEVA CANADA LIMITED

ATC kood:

C09AA01

INN (Rahvusvaheline Nimetus):

CAPTOPRIL

Annus:

50MG

Ravimvorm:

TABLET

Koostis:

CAPTOPRIL 50MG

Manustamisviis:

ORAL

Ühikuid pakis:

100/500/1000

Retsepti tüüp:

Prescription

Terapeutiline ala:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0114954002; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2011-07-05

Toote omadused

_ _
PRODUCT MONOGRAPH
PR
TEVA-CAPTOPRIL
captopril tablets, USP
12.5, 25, 50 and 100 mg
Angiotensin-Converting
Enzyme Inhibitor
Teva Canada Limited
Date of Revision:
February 4, 2021
30 Novopharm Court
Toronto, Ontario
Canada M1B 2K9
www.tevacanada.com
Control Number: 242224
_ _
PRODUCT MONOGRAPH
Pr
TEVA-CAPTOPRIL
captopril tablets, USP
12.5, 25, 50 and 100 mg
THERAPEUTIC CLASSIFICATION
Angiotensin-Converting
Enzyme Inhibitor
ACTIONS AND CLINICAL PHARMACOLOGY
TEVA-CAPTOPRIL (captopril) is an angiotensin converting enzyme
inhibitor
which is used in
the treatment of hypertension and heart failure.
The mechanism of action of captopril has not yet been fully
elucidated. It appears to lower blood
pressure and be an adjunct in the therapy of congestive heart failure
primarily through
suppression of the renin-angiotensin-aldosterone
system; however, there is no consistent
correlation between renin levels and response to the drug. Renin, an
enzyme synthesized by the
kidneys, is released into the circulation where it acts on a plasma
globulin
substrate to produce
angiotensin I, a relatively inactive decapeptide. Angiotensin I is
then converted by angiotensin
converting enzyme (ACE) to angiotensin II, a potent endogenous
vasoconstrictor substance.
Angiotensin II also stimulates aldosterone secretion from the adrenal
cortex, thereby contributing
to sodium and fluid retention.
Captopril prevents the conversion of angiotensin I to angiotensin II
by inhibition of ACE, a
peptidyldipeptide
carboxy hydrolase.
ACE is identical to ‘bradykininase’ and captopril may also
interfere with the degradation of the
vasodepressor peptide, bradykinin.
However, the effectiveness of captopril in therapeutic doses
appears to be unrelated to potentiation of the actions of bradykinin.
Increased concentrations of
bradykinin
or prostaglandin E
2
may also have a role in the therapeutic effect of captopril,
especially in low-renin hypertension.
Inhibition
of ACE results in decreased plasma angiotensin II and increased plasma
renin activity
(PRA), t